National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 2 of 1996)

Overview

The National Health Act 1953, enacted by the Parliament of Australia, was introduced to provide a framework for national health policies and services, addressing the need for a coordinated approach to health care. This legislation established the Pharmaceutical Benefits Scheme (PBS), which aimed to ensure that all Australians have access to necessary medications at affordable prices. One aspect of this Act includes the ability for the Minister for Human Services and Health to declare certain drugs and medicinal preparations as no longer eligible for the benefits under the PBS. This was enacted to address specific health concerns and ensure that resources are allocated to treatments that are both effective and safe. The policy objective here is to maintain the integrity and sustainability of the PBS by periodically reviewing and adjusting the list of covered medications based on clinical evidence and other relevant factors. This particular legislative instrument, F2008B00067, which came into operation on 1 February 1996, is an example of this ongoing review process, as it specifies certain drugs that are to be excluded from the PBS due to their associated risks or lack of efficacy.

Scope and Application

The Pharmaceutical Benefits Declaration under Subsection 85 (2AA) of the National Health Act 1953, made by David Trevor Graham, applies specifically to the drugs and medicinal preparations listed in the Schedule of the Declaration. These drugs include Etretinate, Neostigmine Bromide, Oxymetholone, Thioridazine, and "XP Albumaid". The Declaration removes these substances from the coverage of Part VII of the National Health Act 1953, which pertains to the Pharmaceutical Benefits Scheme. This legislative instrument operates across the Commonwealth of Australia, impacting all persons and entities subject to the National Health Act. The removal of these drugs from the Pharmaceutical Benefits Scheme means they will no longer be subsidised by the Commonwealth under the scheme, affecting their availability and cost to consumers. The Declaration is effective from 1 February 1996, and its application is direct without the need for additional subordinate instruments. There are no exclusions, exemptions, or thresholds specified in this particular Declaration; its application is clear and direct to the listed drugs.

Key Provisions

The main operative sections of this legislative instrument pertain to the removal of specific drugs and medicinal preparations from the scope of Part VII of the National Health Act 1953. According to subsection 85 (2AA) of the Act, the Assistant Secretary, Pharmaceutical Benefits Branch, Department of Human Services and Health, having obtained advice from the Pharmaceutical Benefits Advisory Committee, declares that the drugs and preparations listed in the Schedule will no longer be subject to the provisions of Part VII. This cessation of applicability is effective from 1 February 1996, as stated in clause 1 of the Declaration. The Schedule lists the drugs and preparations affected by this declaration, including Etretinate, Neostigmine Bromide, Oxymetholone, Thioridazine, and “XP Albumaid.” The obligations and requirements imposed by this Act on the relevant parties primarily involve compliance with the decision outlined in the Declaration. Specifically, it is mandated that the drugs and preparations listed in the Schedule are to be treated as no longer subject to the provisions of Part VII of the National Health Act 1953. This means that any regulatory, reimbursement, or other healthcare-related obligations previously imposed on these drugs by Part VII are no longer applicable. The Assistant Secretary's role, as the delegate of the Minister for Human Services and Health, is to ensure that this change is effectively communicated and implemented across all relevant sectors, including healthcare providers, pharmacists, and patients. The consequences for breach of the provisions set out in this legislative instrument are not explicitly detailed within the text. However, it is reasonable to infer that any non-compliance with the declaration could lead to legal repercussions under the broader framework of the National Health Act 1953 or other relevant health regulations. Typically, breaches of health-related legislative instruments could result in civil penalties, enforcement actions, or even criminal charges depending on the severity and intent of the breach. While the specific penalties are not mentioned in this declaration, it is essential for all parties to adhere to the declared changes to avoid potential legal consequences.